American Association for Cancer Research
21598290cd110347-sup-f5_379k.pdf (379.91 kB)

Supplementary Figure 5 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Download (379.91 kB)
journal contribution
posted on 2023-04-03, 20:20 authored by Eric A. Collisson, Christy L. Trejo, Jillian M. Silva, Shenda Gu, James E. Korkola, Laura M. Heiser, Roch-Philippe Charles, Brian A. Rabinovich, Byron Hann, David Dankort, Paul T. Spellman, Wayne A. Phillips, Joe W. Gray, Martin McMahon

PDF file - 379K, Dose response curves of human PDA cell lines treated with either MEK inhibitor GSK1120212, AKT inhibitor GSK690693, or both together



KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA) but remains an intractable pharmacologic target. Consequently, defining RAS effector pathway(s) required for PDA initiation and maintenance is critical to improve treatment of this disease. Here, we show that expression of BRAFV600E, but not PIK3CAH1047R, in the mouse pancreas leads to pancreatic intraepithelial neoplasia (PanIN) lesions. Moreover, concomitant expression of BRAFV600E and TP53R270H result in lethal PDA. We tested pharmacologic inhibitors of RAS effectors against multiple human PDA cell lines. Mitogen-activated protein (MAP)/extracellular signal–regulated (ERK) kinase (MEK) inhibition was highly effective both in vivo and in vitro and was synergistic with AKT inhibition in most cell lines tested. We show that RAF→MEK→ERK signaling is central to the initiation and maintenance of PDA and to rational combination strategies in this disease. These results emphasize the value of leveraging multiple complementary experimental systems to prioritize pathways for effective intervention strategies in PDA.Significance: PDA is difficult to treat, in large part, due to recurrent mutations in the KRAS gene. Here, we define rational treatment approaches for the disease achievable today with existing drug combinations by thorough genetic and pharmacologic dissection of the major KRAS effector pathways, RAF→MEK→ERK and phosphoinositide 3′-kinase (PI3′K)→AKT. Cancer Discov; 2(8); 685–93. ©2012 AACR.Read the Commentary on this article by Hanrahan et al., p. 666.This article is highlighted in the In This Issue feature, p. 653.